BioMar Group enters the week with a striking divergence in insider signals — and that contrast is the most interesting thing on the tape right now.
In early September, CEO Carlos Armando Diaz Verdugo bought 7,900 shares at DKK 125.68, a modest but deliberate open-market purchase that marks a clear vote of confidence from the person closest to the business. That move sits against a far larger transaction in the other direction: parent company Schouw & Co. sold 1.1 million shares in late June at DKK 108.00, a disposal worth roughly DKK 120 million. The 90-day net across all insiders is negative by 1.1 million shares — almost entirely driven by that one parent-level exit. The CEO's September buy, while smaller in absolute terms, came at a materially higher price than the parent's sale and well into the stock's subsequent recovery from DKK 108 to DKK 125.70.
The ownership picture has another layer worth noting. Schouw & Co. still holds approximately 74% of BioMar's shares, so even after its June disposal it remains the dominant shareholder by an enormous margin. DNB Asset Management, Nykredit, and ATP each hold between 2.8% and 3.7%, with the remaining free float thin and tightly held. This structure limits how much institutional repositioning can happen — the float is genuinely small, and any meaningful change in demand from the minority holders tends to register more sharply in the price.
Borrow conditions reflect that thinness, though not in a way that suggests an aggressive short build. Availability is running at around 526% — more than five shares available in the lending pool for every one currently borrowed — which is comfortable territory. Cost to borrow has crept up about 12% over the past month to 4.72%, still modest in absolute terms but a slow, steady drift rather than a spike. The ORTEX short score is in the mid-30s, essentially flat across the past ten days, and well off the 52-week peak utilisation of 46.5%. Nothing in the lending market is signalling a crowded short thesis.
The Street's last formal price target — DKK 138.80 as of mid-August — implies roughly 10% upside from the current level of DKK 125.70. That data is now just outside the window where it can be treated as fully current, and there have been no recent analyst changes on record. What is fresh is the earnings backdrop: Q2 results in August surprised to the upside, with feed volumes up 8% year-over-year and the company lifting full-year guidance. The stock responded — one of the earnings history readings shows a single-day move of more than 10% — though the price has since drifted about 2.5% lower over the past month as the initial enthusiasm faded. The P/E multiple has expanded modestly to around 13.4x over the past 30 days, still a fairly undemanding valuation for a global aquaculture feed business with clear market leadership.
The next scheduled earnings event is November 3. Between now and then, the tension to watch is whether the CEO's personal purchase at these levels draws further conviction from minority institutional holders — or whether Schouw & Co.'s posture on its remaining 74% stake shifts the narrative again.
See the live data behind this article on ORTEX.
Open BIOMAR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
